BioPharma Dive December 6, 2024
Staff

The partners disclosed new study results supporting an approval application for their drug dato-dxd. Amgen, meanwhile, is expanding its manufacturing presence in North Carolina.

Today, a brief rundown of news involving Daiichi Sankyo, Agenus and Amgen, as well as updates from the U.S. PTO, Bluebird bio and Merus that you may have missed.

AstraZeneca and Daiichi Sankyo on Friday revealed new study results supporting their revised approval plans for the closely watched cancer drug datopotamab deruxtecan, or dato-dxd. A pooled analysis from two clinical trials showed dato-dxd kept tumors in check for a median of about six months in people whose non-small cell lung tumors were driven to growth by mutations in the EGFR gene. Among 117 people, median survival...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Investments, Pharma, Pharma / Biotech, Trends
Related Articles:
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
How has U.S. Spending on Health Care Changed Over Time?
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Merck enters $2B licensing deal for weight loss drug

Share This Article